The mutation ratio in p38MAPK or MAP2K3/6 in human cancer is extremely low2 (i.e., Pritchard and Hayward, 2013), suggesting that the implication of an active p38MAPK in cancer is due to the pathologic context of the tumor rather than a genetic alteration in the MAPK or MAP2K able to render a constitutive pathway. The gene discussed is MAP2K3; the disease is cancer.